Christine Kempton

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3540365/publications.pdf

Version: 2024-02-01

122	3,521	147566	149479
papers	citations	31 h-index	56 g-index

125	125	125	2968
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. New England Journal of Medicine, 2018, 379, 811-822.	13.9	489
2	Acquired hemophilia <scp>A</scp>: Updated review of evidence and treatment guidance. American Journal of Hematology, 2017, 92, 695-705.	2.0	267
3	Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factorÂVIII in adults with severe hemophiliaÂA (SPINART). Journal of Thrombosis and Haemostasis, 2013, 11, 1119-1127.	1.9	173
4	How we treat a hemophilia A patient with a factor VIII inhibitor. Blood, 2009, 113, 11-17.	0.6	151
5	Malignant Lymphoma of the Bladder: Evidence From 36 Cases That Low-Grade Lymphoma of the MALT-Type is the Most Common Primary Bladder Lymphoma. American Journal of Surgical Pathology, 1997, 21, 1324-1333.	2.1	130
6	Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood, 2013, 122, 648-657.	0.6	120
7	Toward optimal therapy for inhibitors in hemophilia. Blood, 2014, 124, 3365-3372.	0.6	120
8	Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis, 2017, 15, 2115-2124.	1.9	95
9	Selfâ€reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (Pâ€FiQ) study. Haemophilia, 2017, 23, 556-565.	1.0	90
10	Platelet Heterogeneity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 861-866.	1.1	89
11	Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?. Journal of Thrombosis and Haemostasis, 2005, 3, 1676-1681.	1.9	80
12	<scp>US</scp> Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors. Haemophilia, 2015, 21, 559-567.	1.0	80
13	Fibrinolysis Shutdown and Thrombosis in a COVID-19 ICU. Shock, 2021, 55, 316-320.	1.0	71
14	Pharmacokinetics and safety of OBIâ€1, a recombinant B domainâ€deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia, 2012, 18, 798-804.	1.0	61
15	In nonâ€severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a caseâ€“control study. Journal of Thrombosis and Haemostasis, 2010, 8, 2224-2231.	1.9	60
16	Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. Journal of Thrombosis and Haemostasis, 2006, 4, 2576-2581.	1.9	56
17	Prevalent inhibitors in haemophilia <scp>B</scp> subjects enrolled in the <scp>U</scp>niversal <scp>D</scp>ata <scp>C</scp>ollection database. Haemophilia, 2014, 20, 25-31.	1.0	56
18	The effect of psychological distress on health outcomes: A systematic review and meta-analysis of prospective studies. Journal of Health Psychology, 2020, 25, 227-239.	1.3	52

#	Article	IF	Citations
19	Current and emerging factor VIII replacement products for hemophilia A. Therapeutic Advances in Hematology, 2017, 8, 303-313.	1.1	51
20	Bone density in haemophilia: a single institutional crossâ€sectional study. Haemophilia, 2014, 20, 121-128.	1.0	48
21	Therapeutic plasma exchange for <scp>COVIDâ€19â€associated</scp> hyperviscosity. Transfusion, 2021, 61, 1029-1034.	0.8	47
22	The Impact of Health Literacy on Adherence to Factor Replacement in the Hemophilia Population. Blood, 2014, 124, 2173-2173.	0.6	47
23	Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy. Blood Coagulation and Fibrinolysis, 2015, 26, 383-388.	0.5	46
24	Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network. Journal of Thrombosis and Haemostasis, 2015, 13, 1585-1589.	1.9	44
25	A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Advances, 2018, 2, 1325-1333.	2.5	43
26	A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Human Molecular Genetics, 2013, 22, 1903-1910.	1.4	38
27	A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia, 2014, 20, 230-237.	1.0	37
28	Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patientâ€reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 5-13.	1.1	37
29	Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study. Journal of Thrombosis and Haemostasis, 2015, 13, 1980-1988.	1.9	36
30	Impact of pain and functional impairment in <scp>US</scp> adults with haemophilia: Patientâ€reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (Pâ€FiQ) study. Haemophilia, 2018, 24, 261-270.	1.0	36
31	Eradication of factor viii inhibitors in patients with mild and moderate hemophilia A. American Journal of Hematology, 2012, 87, 933-936.	2.0	34
32	Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective nonâ€interventional study in a realâ€world setting. Haemophilia, 2019, 25, 213-220.	1.0	31
33	Physical activity and functional abilities in adult males with haemophilia: a crossâ€sectional survey from a single <scp>US</scp> haemophilia treatment centre. Haemophilia, 2013, 19, 551-557.	1.0	30
34	Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. Thrombosis and Haemostasis, 2016, 116, 42-49.	1.8	28
35	Internal consistency and item-total correlation of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adult people with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1831-1839.	0.8	27
36	Bone health in persons with haemophilia. Haemophilia, 2015, 21, 568-577.	1.0	26

#	Article	IF	Citations
37	Trends and diagnostic value of D-dimer levels in patients hospitalized with coronavirus disease 2019. Medicine (United States), 2020, 99, e23186.	0.4	25
38	Inhibitors in previously treated patients: a review of the literature. Haemophilia, 2010, 16, 61-65.	1.0	22
39	Physician trust and depression influence adherence to factor replacement: a singleâ€centre crossâ€sectional study. Haemophilia, 2017, 23, 98-104.	1.0	21
40	Factors associated with pain severity, pain interference, and perception of functional abilities independent of joint status in <scp>US</scp> adults with hemophilia: Multivariable analysis of the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 25-33.	1.1	21
41	Toward optimal therapy for inhibitors in hemophilia. Hematology American Society of Hematology Education Program, 2014, 2014, 364-371.	0.9	20
42	Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1369-1380.	0.8	20
43	Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon Resonance. PLoS ONE, 2013, 8, e61120.	1.1	20
44	Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein. Blood, 2011, 117, 3190-3198.	0.6	19
45	Distress in patients with bleeding disorders: a single institutional crossâ€sectional study. Haemophilia, 2015, 21, e456-64.	1.0	18
46	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 528-541.	1.0	18
47	Antithrombin Affects Hemostatic Response to Recombinant Activated Factor VII in Factor VIII Deficient Plasma. Anesthesia and Analgesia, 2008, 106, 719-724.	1.1	17
48	Known-group validity of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1745-1753.	0.8	17
49	Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice. Blood Advances, 2019, 3, 288-300.	2.5	17
50	Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1603-1612.	0.8	15
51	Pharmacokinetics, safety and efficacy of a recombinant factor <scp>IX</scp> product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia, 2018, 24, 104-112.	1.0	14
52	Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS. Haemophilia, 2020, 26, 1072-1080.	1.0	14
53	Management of comorbidities in haemophilia. Haemophilia, 2021, 27, 37-45.	1.0	14
54	F5â€Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FVâ€short production. Journal of Thrombosis and Haemostasis, 2021, 19, 1653-1665.	1.9	14

#	Article	IF	Citations
55	A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.. Blood, 2007, 110, 783-783.	0.6	14
56	A subset of high-titer antiâ€“factor VIII A2 domain antibodies is responsive to treatment with factor VIII. Blood, 2016, 127, 2028-2034.	0.6	13
57	Clinical Outcomes of Critically Ill Patients with COVID-19 by Race. Journal of Racial and Ethnic Health Disparities, 2022, 9, 385-389.	1.8	12
58	The role of disease severity in influencing body mass index in people with haemophilia: a singleâ€institutional crossâ€sectional study. Haemophilia, 2014, 20, 190-195.	1.0	11
59	Emicizumab for hemophilia A without inhibitors. Expert Review of Hematology, 2019, 12, 515-524.	1.0	11
60	The Bâ€Natural studyâ€”The outcome of immune tolerance induction therapy in patients with severe haemophilia B. Haemophilia, 2021, 27, 802-813.	1.0	11
61	Survey of the antiâ€“factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescenceâ€based immunoassay. Journal of Thrombosis and Haemostasis, 2016, 14, 1931-1940.	1.9	10
62	Validation of a new instrument to measure diseaseâ€related distress among patients with haemophilia. Haemophilia, 2021, 27, 60-68.	1.0	10
63	Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia, 2021, 27, 221-228.	1.0	10
64	Evaluation of factor VIII pharmacokinetics and antiâ€factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII. Haemophilia, 2011, 17, 155-156.	1.0	9
65	HLA-DRB1â€“factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study. Blood Advances, 2018, 2, 1750-1755.	2.5	9
66	Validation of an admission coagulation panel for risk stratification of COVID-19 patients. PLoS ONE, 2021, 16, e0248230.	1.1	9
67	Ulcerative Colitis Presenting as Purpura Fulminans. Inflammatory Bowel Diseases, 2001, 7, 319-322.	0.9	8
68	Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. Haemophilia, 2019, 25, 867-875.	1.0	8
69	An evaluation of PROMIS health domains in adults with haemophilia: A crossâ€sectional study. Haemophilia, 2021, 27, 375-382.	1.0	8
70	Epidemiology of Inhibitors in Persons with Severe Hemophilia a in the United States: Analyses of a National Database. Blood, 2018, 132, 2470-2470.	0.6	7
71	Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3. Blood, 2019, 134, 626-626.	0.6	7
72	Diseaseâ€related distress among adults with haemophilia: A qualitative study. Haemophilia, 2019, 25, 988-995.	1.0	6

#	Article	IF	Citations
73	Evaluation of Treatment-Dose Enoxaparin in Acutely Ill Morbidly Obese Patients at an Academic Medical Center: A Randomized Clinical Trial. Annals of Pharmacotherapy, 2019, 53, 567-573.	0.9	6
74	Natural history study of factor IX deficiency with focus on treatment and complications (Bâ€Natural). Haemophilia, 2021, 27, 49-59.	1.0	6
75	Shortening the Haemophilia Activities List (HAL) from 42 items to 18 items. Haemophilia, 2021, 27, 1062-1070.	1.0	6
76	Mortality Trends and Causes of Death in Persons with Hemophilia in the United States, 1999-2014. Blood, 2017, 130, 755-755.	0.6	6
77	Detection of Non Inhibitory Binding Antibodies to Von Willebrand Factor Affecting the Clearance of VWF:Ag in Von Willebrand Disease. Blood, 2011, 118, 2275-2275.	0.6	5
78	Quality of life in a large multinational haemophilia B cohort (The Bâ€Natural study) â€“ Unmet needs remain. Haemophilia, 2022, 28, 453-461.	1.0	5
79	Mitral valve repair in a Jehovah's witness with haemophilia A with high-titre inhibitor. Haemophilia, 2015, 21, e523-e525.	1.0	4
80	A crossâ€sectional study of nonâ€attendance among patients at a <scp>US</scp> hemophilia treatment center 2010â€2014. Haemophilia, 2018, 24, 902-910.	1.0	4
81	Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. Blood Advances, 2020, 4, 4739-4747.	2.5	4
82	Management of inhibitors in persons with nonâ€severe hemophilia <scp>A</scp> in the <scp>United States</scp>. American Journal of Hematology, 2021, 96, E9-E11.	2.0	4
83	Prophylaxis in hemophilia: how much is enough?. Blood, 2021, 137, 1709-1711.	0.6	4
84	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood, 2014, 124, 2836-2836.	0.6	4
85	Continuation of all-trans retinoic acid despite the development of scrotal ulcerations in a black male. Journal of Oncology Pharmacy Practice, 2015, 21, 393-395.	0.5	3
86	Exploring changes in distress among individuals with bleeding disorders: What is linked to improvements in distress?. Journal of Health Psychology, 2019, 24, 1724-1733.	1.3	3
87	Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia, 2021, 27, 211-220.	1.0	3
88	Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Blood, 2015, 126, 39-39.	0.6	3
89	Copper Deficiency Remains An Underappreciated Cause of Ineffective Hematopoiesis. Blood, 2008, 112, 3094-3094.	0.6	3
90	Comparing direct oral anticoagulants and vitamin K antagonist use in morbidly obese patients with venous thromboembolism: A single center retrospective cohort study. EJHaem, 2022, 3, 457-462.	0.4	3

#	Article	IF	Citations
91	Use of factor VIII after inhibitor clearance in patients with moderate haemophilia A: a case series. Haemophilia, 2014, 20, e344-e346.	1.0	2
92	Thrombocytopenia Induced by Polysulfone Dialysis Membranes. American Journal of Case Reports, 2021, 22, e932045.	0.3	2
93	All-Cause and Inhibitor-Related Mortality in Non-Severe Hemophilia Î‘ Patients in the United States. Blood, 2019, 134, 902-902.	0.6	2
94	Recombinant Human Von Willebrand Factor (rhVWF): First-In-Human Study Evaluating Pharmacokinetics, Demonstrating Safety and Tolerability In Type 3 Von Willebrand Disease. Blood, 2010, 116, 237-237.	0.6	2
95	Natural History Of Inhibitor Recurrence Following Successful Immune Tolerance Induction. Blood, 2013, 122, 1106-1106.	0.6	2
96	Postoperative Deep Vein Thrombosis (DVT) In Patients With Hemophilia Undergoing Major Orthopedic Surgery. Blood, 2013, 122, 207-207.	0.6	2
97	Linear and Logistic Regression Models of Patient-Reported Outcomes and Patient Characteristics in US Adults with Hemophilia from the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Blood, 2016, 128, 252-252.	0.6	2
98	Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors. Journal of Medical Economics, 2022, 25, 984-992.	1.0	2
99	Validation of Instrument to Assess Hemophilia-Related Distress. Blood, 2019, 134, 936-936.	0.6	1
100	COAT Platelet Formation Is P2Y12-Dependent.. Blood, 2004, 104, 1569-1569.	0.6	1
101	Non-Factor VIII Coagulation Proteins Fail to Predict Joint Outcome in Severe Hemophilia a. Blood, 2015, 126, 2289-2289.	0.6	1
102	Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study. Blood, 2018, 132, 383-383.	0.6	1
103	Factor VII Concentrates. , 2009, , 739-741.		0
104	Prothrombin Complex Concentrates. , 2009, , 721-723.		0
105	Expecting the Unexpected. Journal of Oncology Practice, 2016, 12, 533-534.	2.5	0
106	Coagulation Factor Inhibitors: Diagnosis and Management. , 2016, , 263-272.		0
107	Moving from parked to neutral(izing). Blood, 2017, 129, 1233-1234.	0.6	0
108	What can we learn from using formal patientâ€reported outcome instruments to assess pain, functional impairment, anxiety, and depression in <scp>US</scp> adults with hemophilia?. European Journal of Haematology, 2018, 100, 3-4.	1.1	0

#	Article	IF	Citations
109	Bleeding Disorders in Pregnancy. , 2019, , 711-718.		0
110	Acquired Coagulation Factor Inhibitors. , 2019, , 761-766.		0
111	Laboratory Evaluation of Thrombotic Thrombocytopenic Purpura. , 2019, , 919-923.		0
112	Outcomes of direct oral anticoagulant- and warfarin-associated hemorrhage: A single center retrospective cohort study. Thrombosis Research, 2020, 189, 128-131.	0.8	0
113	Bleeding Disorders in Pregnancy. , 2009, , 555-559.		0
114	Acquired Coagulation Factor Inhibitors. , 2009, , 595-600.		0
115	ADAMTS13 Testing. , 2009, , 635-638.		0
116	Predictors of Von Willebrand Disease In Children: A Case-Control Study. Blood, 2010, 116, 712-712.	0.6	0
117	N1922S Mutation In the Factor VIII A3 Domain Produces a Rate-Limiting, Domain-Specific Folding Defect Leading to Hyposecretion of a Functional Protein. Blood, 2010, 116, 2209-2209.	0.6	0
118	Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis. Blood, 2011, 118, 2267-2267.	0.6	0
119	Numeracy in Patients with Hemophilia. Blood, 2015, 126, 40-40.	0.6	0
120	Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study. Blood, 2018, 132, 2479-2479.	0.6	0
121	An Evaluation of Promis Health Domains in Adults with Hemophilia: A Cross-Sectional Study. Blood, 2018, 132, 493-493.	0.6	0
122	Outcomes of Direct Oral Anticoagulant- and Warfarin-Associated Hemorrhage: A Single Center Retrospective Cohort Study. Blood, 2018, 132, 826-826.	0.6	0